Zai Lab (ZLAB) Competitors $33.43 -0.42 (-1.24%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZLAB vs. SMMT, RDY, ASND, VTRS, ROIV, QGEN, BBIO, MRNA, ELAN, and VRNAShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Zai Lab (NASDAQ:ZLAB) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Do insiders & institutionals hold more shares of ZLAB or SMMT? 41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate ZLAB or SMMT? Zai Lab presently has a consensus target price of $56.35, suggesting a potential upside of 67.62%. Summit Therapeutics has a consensus target price of $31.29, suggesting a potential upside of 52.09%. Given Zai Lab's stronger consensus rating and higher possible upside, research analysts clearly believe Zai Lab is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Summit Therapeutics 4 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.53 Is ZLAB or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -49.68%. Zai Lab's return on equity of -27.32% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-49.68% -27.32% -18.85% Summit Therapeutics N/A -208.64%-181.28% Which has more risk and volatility, ZLAB or SMMT? Zai Lab has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, meaning that its stock price is 213% less volatile than the S&P 500. Does the media refer more to ZLAB or SMMT? In the previous week, Summit Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Summit Therapeutics and 1 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.16 beat Summit Therapeutics' score of 0.49 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, ZLAB or SMMT? Summit Therapeutics has lower revenue, but higher earnings than Zai Lab. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M9.42-$257.10M-$2.04-16.48Summit TherapeuticsN/AN/A-$221.32M-$1.01-20.37 SummaryZai Lab beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks. Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.77B$3.34B$6.11B$10.55BDividend YieldN/A2.29%5.68%4.67%P/E Ratio-16.5522.0177.7326.85Price / Sales9.42264.87520.32204.70Price / CashN/A46.3737.8961.20Price / Book4.389.9312.606.57Net Income-$257.10M-$52.59M$3.30B$276.93M7 Day Performance6.32%5.49%28,071.81%2.88%1 Month Performance7.40%12.83%28,977.71%9.87%1 Year Performance36.54%29.86%35,775.90%32.97% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab2.805 of 5 stars$33.43-1.2%$56.35+68.6%+32.2%$3.73B$398.99M-16.361,869Positive NewsSMMTSummit Therapeutics3.1002 of 5 stars$19.10+1.1%$31.87+66.8%+6.8%$14.03B$700K-18.91110RDYDr. Reddy's Laboratories3.1189 of 5 stars$14.59-1.9%$16.95+16.2%-11.2%$12.42B$3.81B22.1127,811Positive NewsASNDAscendis Pharma A/S3.377 of 5 stars$196.42-0.6%$244.36+24.4%+37.4%$12.18B$393.54M-38.071,017High Trading VolumeVTRSViatris1.4786 of 5 stars$9.79-1.1%$10.40+6.2%-11.9%$11.54B$14.74B-3.3832,000ROIVRoivant Sciences3.7612 of 5 stars$14.94-0.7%$19.94+33.5%+41.7%$10.27B$29.05M-21.34860QGENQIAGEN4.4899 of 5 stars$45.72-0.5%$49.69+8.7%+7.3%$10.21B$1.98B27.015,765Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.287 of 5 stars$51.54-1.6%$63.94+24.1%+112.4%$10.01B$221.90M-12.60400MRNAModerna4.3623 of 5 stars$26.56+5.2%$41.81+57.4%-55.1%$9.82B$3.24B-3.535,800Options VolumeELANElanco Animal Health2.7002 of 5 stars$19.08-0.6%$17.33-9.2%+41.7%$9.54B$4.44B22.199,000Positive NewsVRNAVerona Pharma PLC American Depositary Share1.9323 of 5 stars$106.25+0.2%$109.00+2.6%+272.1%$9.14B$42.28M-107.3230Positive News Related Companies and Tools Related Companies Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Roivant Sciences Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
